FDA approval (along with TGA approval and soft launch here) and their associated costs were mentioned during the prospectus dated 23 July. Cash raised during launch helped pay for these so I assume they were done when the coy floated.
Haven't looked to hard into it so you might like to delve a little deeper if inclined.
Updated Figures, page-29
Add IME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.89M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 17167 | 1 |
View Market Depth
| Last trade - 16.12pm 03/12/2024 (20 minute delay) ? |
| IME (ASX) Chart |
Day chart unavailable
